2-9 They do this by: Building confidence and self-efficacy by empowering patients to actively engage with their treatment journey Educating patients to address the widespread misconception that obesity is not a disease, with 40% of patients unaware of this and 80% feeling solely responsible for their condition Implementing a whole-health approach to redefine treatment success, focus on overall health outcomes, not just weight loss Setting realistic expectations which prepares patients for the possibility of losing less weight than expected while still achieving significant health benefits Supporting medication adherence by providing tools for reminders, routines, titration guidance, and addressing injection anxiety Driving medication persistence as a result of setting realistic expectations and frame treatment around long-term health gains rather than short-term weight loss Mitigating side effects through equipping patients to self-manage common side effects through proactive tracking and helping them connect the dots Want to learn even more about how digital solutions can unlock the full potential of GLP-1 therapies
Normal dosages range from 100 mg 500 mg in dried herb or liposomal forms, however, most supplements and studies are in the 100 mg range
After securing approval, you receive comprehensive support, including appointment reminders, prescription updates, pharmacy services, and 24/7 access to your care team
But new data from the SURMOUNT-OSA trials suggests incretin-based therapy with tirzepatide could be the answer
IGF-1 LR3 has two molecular modifications, an arginine substitution at position 3 and a 13-amino acid N-terminal extension, that prevent IGFBP binding
FDA Approves Oral Semaglutide as the First GLP-1 Pill for Weight Loss The FDAs recent approval of oral semaglutide marks a revolutionary milestone in obesity medicine, introducing the first daily pill to deliver the powerful weight loss results previously restricted to injectable therapies
